Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 5/20 | 0.65 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SELL | P14151 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SELP | P16109 | 1/20 | 0.42 |
| ▸ | FUT4 | P22083 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28143645 | 0.85 | TPMT (0.54) | TPMTCA1CA2CA9CA12 | |
| SCHEMBL3715241 | 0.85 | TPMT (0.54) | TPMTCA1CA2CA9CA12 | |
| SCHEMBL16064373 | 0.85 | TPMT (0.54) | TPMTCA1CA2CA9CA12 | |
| SCHEMBL5068048 | 0.83 | TPMT (0.47) | TPMTCA1CA2CA9CA12 | |
| SCHEMBL18009390 | 0.80 | CA12 (0.56) | TPMTCA1CA2CA9CA12 | |
| SCHEMBL122324 | 0.79 | TPMT (1.00) | TPMTCA1CA2CA9CA12 | |
| SCHEMBL3708951 | 0.79 | LMNA (0.56) | TPMTALDH1A1LMNAMAPTTSHR | |
| SCHEMBL22982377 | 0.78 | CA5A (0.46) | TPMTCA1CA2CA9LMNA | |
| SCHEMBL11878620 | 0.78 | CA1 (0.41) | TPMTCA1CA2CA9ALDH1A1 | |
| SCHEMBL1613916 | 0.77 | TPMT (0.68) | TPMTCA1CA2CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-114057600-A | X-ray developable molecule, drug-loaded embolism microsphere and preparation method thereof | 上海汇禾医疗科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| EP-1799791-B1 | PHOTOCROSSLINKABLE MATERIALS | ROLIC AG (CH) | 2016-01-13 | — | — | EP | claimed |
| US-7687118-B2 | Photocrosslinkable materials | ROLIC AG (CH) | 2010-03-30 | — | — | US | claimed |
| US-20080069968-A1 | Photocrosslinkable Materials | ROLIC AG (CH) | 2008-03-20 | — | — | US | claimed |
| EP-1799791-A1 | PHOTOCROSSLINKABLE MATERIALS | Rolic AG (CH) | 2007-06-27 | — | — | EP | claimed |
| WO-2006039824-A1 | PHOTOCROSSLINKABLE MATERIALS | ROLIC AG (CH) | 2006-04-20 | — | — | WO | claimed |
| US-RE37303-E1 | Imidazole compounds and their therapeutic applications | INSTITUT NATIONAL DEL LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2001-07-31 | — | — | US | claimed |
| EP-0597088-B1 | NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATIONS | INST NAT SANTE RECH MED (FR) | 2000-12-06 | — | — | EP | claimed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | claimed |
| US-20260049178-A1 | CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250180952-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-06-05 | — | — | US | disclosed |
| EP-4493638-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-01-22 | — | — | EP | disclosed |
| CN-118871548-A | Photoalignment materials | 罗利克技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-6214877-B1 | ANTIDIABETIC AGENTS; MODULATOR OF GLUCOSE CONCENTRATION | WYETH | 2001-04-10 | — | — | US | disclosed |
| EP-1077929-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061410-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
| US-5708171-A | HISTAMINE H3-RECEPTOR ANTAGONIST | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 1998-01-13 | — | — | US | disclosed |
| US-5559113-A | ANTAGONISTS TO HISTAMINE H3 RECEPTORS, SEDATIVES, ANTICONVULSANTS, ANTIULCER AGENTS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | 1996-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049178-A1 | CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM | NPPA, MACF1, IGF1R | TPMT 3130/4885CA1 1009/4885CA2 650/4885 |
| US-20080069968-A1 | Photocrosslinkable Materials | PARG, VSIR, IGLV6-57 | TPMT 4538/4885CA1 882/4885CA2 3560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.